Pharmacokinetics of the M1-agonist talsaclidine in mouse, rat, rabbit and monkey, and extrapolation to man

References

• ADAMUS, W. S., LEONARD, J. P. and TRöGER, W., 1995, Phase I clinical trials with WAL 2014, a new muscarinic agonist for the treatment of Alzheimer's disease. Life Science, 56, 883–890.
   Google Scholar
• ARNT, J., LEMBOL, H. L., MEIER, E. and PEDERSEN, H., 1992, Discriminative stimulus properties of the muscarinic receptor agonists Lu 26-046 and 0-Me-THP0 in rats: evidence for involvement of different muscarinic receptor subtypes. European Journal of Pharmacology, 218, 159–169.
   PubMedGoogle Scholar
• BARNER, E. L. and GRAY, S. L., 1998, Donepezil use in Alzheimer disease. Annals of Pharmacotherapy, 32, 70–77.
   PubMed Web of Science ®Google Scholar
• BROMIDGE, S. M., BROWN, F., CASSIDY, F., CLARK, M. S., DABBS, S., HADLEY, M. S., HAWKINS, J., LOUDON, J. M., NAYLOR, C. B., ORLEK, B. S. and RILEY, G. J., 1997, Design of [R-(Z)] -(+)-alpha- (methoxyimino)-1-azabicyclo [2.2 .2] octane-3-acetonitrile (SB 202026), a functionally selec-tive azabicyclic muscarinic M1 agonist incorporating the N-methoxy imidoyl nitrile group as a novel ester bioisostere. Journal of Medical Chemistry, 40, 4265–4280.
   PubMed Web of Science ®Google Scholar
• BYMASTER, F. P., CARTER, P. A., PETERS, S. C., ZHANG, W., WARD, J. S., MITCH, C. H., CALLIGARO, D. 0., WHITESITT, C. A., DELAPP, N., SHANNON, H. E., RIMVALL, K., JEPPESEN, L., SHEARDOWN, M. J., FINK-JENSEN, A. and SAUERBERG, P., 1998, Xanomeline compared with other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects. Brain Research, 795, 179–190.
   Google Scholar
• CHIOU, W. L., ROBBIE, G., CHUNG, S. M., Wu, T. C. and Ma, C., 1998, Correlation of plasma clearance of 54 extensively metabolized drugs between humans and rats: mean allometric coefficient of 0.66. Pharmaceutical Research, 15, 1474–1479.
   PubMed Web of Science ®Google Scholar
• DAVIES, B., ANDREWES, D., STARGATT, R., AMES, D., TUCKWELL, V. and DAVI S., 1989, Tacrine in Alzheimer's disease. Lancet, II, 163–164.
   Google Scholar
• DAVIS, B. and MORRIS, T., 1993, Physiological parameters in laboratory animals and humans. Pharmaceutical Research, 10, 1093–1095.
   PubMed Web of Science ®Google Scholar
• DELAPP, N., Wu, S., BELAGAJE, R., JOHNSTONE, E., LITTLE, S., SHANNON, H., BYMASTER, F., CALLIGARO, D., MITCH, C., WHITESITT, C., WARD, J., SHEARDOWN, M., FINK-JENSEN, A., JEPPESEN, L., THOMSEN, C. and SAUERBERG, P., 1998, Effects of the M1 agonist xanomeline on processing of human beta-amyloid precursor protein (FAD, Swedish mutant) transfected into Chinese hamster ovary-m1 cells. Biochemical and Biophysical Research Communications, 244, 156–160.
   Google Scholar
• ENSINGER, H. A., BECHTEL, W. D., BIRKE, F. W., MENDLA, K. D., MIERAU, J., SPECK, G. and TRoGER, W., 1997, WAL 2014 FU (talsaclidine): a preferentially neuron activating muscarinic agonist for the treatment of Alzheimer's disease. Drug Development and Research, 40, 144–157.
   Google Scholar
• ENSINGER, H. A., DOODS, H. N., IMMEL-SEHR, A. R., KUHN, F. J., LAMBRECHT, G., MENDLA, K. D., MUELLER, R. E., MUTSCHLER, E., SAGRADA, A., WALTHER, G. and HAMMER, R., 1993, WAL 2014—a muscarinic agonist with preferential neuron-stimulating properties. Life Sciences, 52, 473–480.
   Google Scholar
• GIACOBINI, E., 1998, Invited Review: Cholinesterase inhibitors for Alzheimer's disease therapy: from tacrine to future applications. Neurochemistry International, 32, 413419.
   Google Scholar
• GIBALDI, M. and PERRIER, D., 1982, Pharmacokinetks, 2nd edn (New York: Marcel Dekker), pp. 409–417.
   Google Scholar
• GLEITER, C. H. and GUNDERT-REMY, 1996, Gender differences in pharmacokinetics European Journal of Drug Metabolism, 21, 123–128.
   Google Scholar
• HEINZEL, G., WOLOSZCZAK, R. and THOMANN, P., 1993 Non-compartmental analyses: methods. In TOPFIT version 2.0: Pharmacokinetic and Pharmacodynamk Analysis System for the PC (New York: Gustav Fisher), pp. 2.6-29.
   Google Scholar
• HULME, E. C., BIRDSALLN. J. and BUCKLEY N. J., 1990, Muscarinic receptor subtypes. [Review]. Annual Reviews of Pharmacology and Toxicology, 30, 633–673.
   Google Scholar
• INGs, R. M. J., 1990, Interspecies scaling and comparison in drug development and toxicokinetics. Xenobiotica, 20, 1201–1231.
   PubMed Web of Science ®Google Scholar
• LAWRENCE A. D. and SAHAKIAN B. J., 1998, The cognitive psychopharmacology of Alzheimer's disease: focus on cholinergic systems [Review]. Neurochemistry Research, 23, 787–794.
   PubMed Web of Science ®Google Scholar
• LIN, J. H., 1998, Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. Drug Metabolism and Disposition, 26, 1202–1212.
   PubMed Web of Science ®Google Scholar
• LIN, J. H., CHIBA, M., CHEN, I. W., NISHIME, J. A. and VASTAG, K. J., 1996, Sex-dependent pharmacokinetics of indinavir : in vivo and in vitro evidence. Drug Metabolism and Disposition, 24, 1298–1306.
   PubMed Web of Science ®Google Scholar
• MESSER, W. S. JR, ELLERBROCK, B., PRICE, M. and Hoss, W., 1989, Autoradiographic analyses of agonist binding to muscarinic receptor subtypes. Biochemical Pharmacology, 38, 837–850.
   Google Scholar
• PADE, V. and STAVCHANSKY, S., 1998, Link between drug absorption and permeability measurements in CaCo-2 cells. Journal of Pharmaceutical Science, 87, 1604–1607.
   PubMed Web of Science ®Google Scholar
• PRAKASH, C. and SOLIMAN, V., 1997, Metabolism and excretion of a novel antianxiety drug candidate, CP-93,393, in Long—Evans rats. Drug Metabolism and Disposition, 25,1288–1297.
   PubMed Web of Science ®Google Scholar
• ROGERS, S. L., DOODY, R. S., Molls, R. C. and FRIEDHOFF, L. T., 1998, Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Archives of Internal Medicine, 158, 1021–1031.
   PubMed Web of Science ®Google Scholar
• SHAW, V. P., MIDHA, K. K., DIGHE, S., MCGILVERAY, I. J., SKELLY, J. P., YACOBI, A., LAYLOFF, T., VISWANATHAN, C. T., CooK, C. E., McDowALL, R. D., PITTMANN, K. A. and SPECTOR, S., 1992 Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Pharmaceutical Research, 9, 588–592.
   Google Scholar
• SRAMEK, J. J., FORREST, M., MENGEL, H., JHEE, S. S., HOURANI, J. and CUTLER, N. R., 1998, A bridging study of LU 25-109 in patients with probable Alzheimer's disease. Life Sciences, 62, 195–202.
   PubMedGoogle Scholar
• TANAKA, Y., DEGUCHI, Y., Ism', I. and TERAI, T., 1991, Sex differences in excretion of zenarestat in rat. Xenobiotica, 21, 1119–1125.
   Google Scholar
• ULLRICH, K. J., 1994, Specificity of transporters for organic anions and organic cations in the kidney. Biochimica et Biophysica Acta, 1197, 45–62.
   PubMed Web of Science ®Google Scholar